What Cancer Stage Is a PI-RADS 4 Score?

A PI-RADS 4 score is not a cancer stage at all. PI-RADS and cancer staging are two entirely different systems that get confused constantly, and the mix-up causes real anxiety for people staring at an MRI report they did not expect to receive. PI-RADS is a score radiologists assign to a suspicious area on a prostate MRI, rating how likely it is to be clinically significant cancer on a scale from 1 to 5. Cancer staging, by contrast, only happens after cancer has been confirmed and describes how far it has spread. A PI-RADS 4 score means “clinically significant cancer is likely,” but it does not confirm cancer exists, let alone tell you what stage it would be.

What PI-RADS 4 Actually Means

PI-RADS stands for Prostate Imaging Reporting and Data System. It was developed so radiologists reading prostate MRIs would have a shared language for describing what they see. The scale runs from 1 (very low suspicion) to 5 (very high suspicion that clinically significant cancer is present). A score of 4 means “clinically significant cancer is likely.” That phrasing is deliberate: likely, not certain. The score is based on the appearance of a lesion on different MRI sequences, primarily how tissue looks on diffusion-weighted imaging and T2-weighted imaging, depending on where in the prostate the lesion sits.

“Clinically significant” has a specific meaning in this context. It generally refers to cancer with a Gleason score of 7 or higher, a tumor volume of at least 0.5 cubic centimeters, or a tumor that has grown beyond the prostate capsule.¹ In other words, cancer that would probably need treatment rather than just monitoring. A PI-RADS 4 score is the radiologist’s way of flagging that the MRI pattern looks concerning enough to warrant a biopsy, but it says nothing about how far cancer has or has not spread.

How Cancer Staging Differs

Prostate cancer staging uses the TNM system maintained by the American Joint Committee on Cancer. The “T” describes how far the primary tumor extends (confined to the prostate, through the capsule, into nearby structures), the “N” indicates whether nearby lymph nodes are involved, and the “M” tells whether cancer has spread to distant sites. Under the current eighth edition of the AJCC staging manual, pathologically organ-confined disease is classified as pT2 without further subdivision by size or laterality, and the system now incorporates both Gleason score and the newer grade group system alongside PSA levels to assign an overall prognostic stage group.²

You cannot derive a cancer stage from a PI-RADS score. A man with a PI-RADS 4 lesion could turn out to have no cancer at all. He could have low-grade cancer confined entirely within the prostate (stage I or II). Or he could have higher-grade cancer that has started to push beyond the capsule (stage III). The PI-RADS score simply tells the clinical team that the MRI pattern is suspicious enough to investigate further. Staging comes later, after tissue has been obtained and examined under a microscope, and sometimes not fully until after surgery.

How Often PI-RADS 4 Leads to a Cancer Diagnosis

This is the question most people actually want answered when they look up their PI-RADS score. The short version: roughly 4 in 10 PI-RADS 4 lesions turn out to harbor clinically significant prostate cancer on biopsy, though published numbers range widely depending on the study population and biopsy technique.

A systematic review and meta-analysis pooling data from multiple studies found that the positive predictive value of PI-RADS 4 for clinically significant cancer was about 40%.³ Individual studies report higher or lower figures. One single-center analysis found a positive predictive value of about 52% for any prostate cancer among PI-RADS 4 lesions.⁴ Another reported clinically significant cancer rates of about 65% for PI-RADS 4 lesions in their cohort.⁵ An AI-assisted study found biopsy-confirmed clinically significant cancer in about 40% of radiologist-assigned PI-RADS 4 lesions.⁶

What these numbers mean in practice is that a PI-RADS 4 score sits in genuinely uncertain territory. It is substantially more worrisome than PI-RADS 3, where the meta-analytic positive predictive value for clinically significant cancer drops to about 13%, and considerably less alarming than PI-RADS 5, where it climbs to around 69%.³ But a coin-flip-ish probability of significant cancer is exactly why nearly all urological guidelines recommend biopsy for PI-RADS 4 findings.

Why PI-RADS 4 Covers Such a Wide Range

PI-RADS 4 is arguably the broadest and most heterogeneous category in the scoring system. A lesion can land here because it has a clearly abnormal diffusion signal in the peripheral zone but does not quite meet the size threshold for PI-RADS 5, or because it is a transition-zone nodule that looks distinctly different from typical benign tissue but lacks unambiguous features of aggressive cancer. The category also picks up lesions where contrast enhancement tips the scale upward from a PI-RADS 3.

Because of this breadth, some researchers have explored subdividing PI-RADS 4 into higher-suspicion and lower-suspicion subcategories. One quality-improvement study assigned PI-RADS 4 lesions to “4+” (higher suspicion based on lower apparent diffusion coefficient values) and “4−” (lower suspicion) groups. The results were striking: about 61% of lesions in the 4+ subcategory contained clinically significant cancer, compared with only about 17% in the 4− subcategory.⁷ That kind of split suggests not all PI-RADS 4 scores carry the same weight, and the clinical conversation after receiving one should probably reflect where in the category the lesion falls.

Lesion Size and Other Factors That Shift the Odds

Beyond the MRI appearance itself, the physical size of a PI-RADS 4 lesion matters. One study analyzing transperineal biopsies found that lesions larger than about 8.5 millimeters had roughly 2.3 times the risk of harboring clinically significant cancer compared with smaller lesions.⁵ PSA density, age, and family history also factor into your urologist’s overall risk assessment. Some centers are also incorporating blood-based biomarkers alongside MRI results to refine who truly needs a biopsy and who might safely defer.⁸

What Happens at Biopsy

If your urologist recommends a biopsy after a PI-RADS 4 finding, the standard approach today combines two techniques: a targeted biopsy aimed directly at the suspicious lesion seen on MRI, and a systematic biopsy that samples tissue from across the prostate in a grid-like pattern. Research consistently shows that combining both methods catches the most cancers. One prospective study found that using only one biopsy method alone would have missed anywhere from about 12% to 33% of clinically significant cancers, depending on which method was used in isolation.⁹ For PI-RADS 4 specifically, targeted biopsy both improved the detection of clinically significant cancer and reduced the detection of low-grade cancers that might not need treatment.¹⁰

When PI-RADS 4 Does Find Cancer, What Stage Is It Usually?

Now we can address the question people really want answered, even though it requires several caveats. When cancer is confirmed after a PI-RADS 4 finding, the stage depends on factors the MRI score alone cannot determine: the Gleason grade of the tumor cells, PSA level, and whether the tumor extends beyond the prostate capsule. However, research gives us some patterns.

A study examining surgical outcomes found that patients with higher PI-RADS scores were significantly more likely to be “upstaged” when pathologists examined the removed prostate, meaning the cancer turned out to be more advanced than the biopsy suggested. Each one-point increase in PI-RADS score roughly doubled the odds of upstaging, and lymph node metastases were found only in patients who had PI-RADS 4 or 5 lesions.² That does not mean every PI-RADS 4 cancer is advanced. Many PI-RADS 4 cancers turn out to be organ-confined (stage II), but there is a meaningful proportion where the cancer has begun to breach the prostate capsule (stage III), which is why the MRI flagged it as suspicious in the first place.

MRI can also provide clues about local extent before surgery. Extracapsular extension and seminal vesicle invasion are features that push cancer from stage II into stage III. One study of patients with PI-RADS 4 and 5 lesions found that targeted biopsies identified extracapsular extension that systematic biopsies had missed entirely.¹¹ However, MRI is not perfect at detecting these features. One comparison found that multiparametric MRI had a sensitivity of about 66% for extracapsular extension, meaning it misses roughly a third of cases.¹² Newer techniques such as PSMA-PET/MRI may improve that sensitivity, with one study showing detection rates climbing from 28% to 47% for extracapsular extension when PSMA imaging was added.¹³

False Positives and the Pitfalls of PI-RADS 4

Remember that roughly half or more of PI-RADS 4 lesions turn out to be benign on biopsy. Several non-cancerous conditions can mimic cancer on prostate MRI. Inflammation (prostatitis), benign prostatic hyperplasia nodules, prostatic calcifications, and even normal anatomical structures like the central zone or anterior fibromuscular stroma can all create MRI appearances that look suspicious to a radiologist.¹⁴ Granulomatous prostatitis, which can occur after certain bladder cancer treatments or infections, is a particularly notorious mimic.¹⁵

This false-positive rate is one reason PI-RADS 4 generates so much anxiety. You receive a report that says cancer is “likely,” but the statistical reality is that there is a genuine chance, perhaps close to even odds, that nothing serious is going on. The flip side is equally important: a negative biopsy after a PI-RADS 4 finding does not always mean the area is definitively clear.

What Happens If the Biopsy Is Negative

A negative biopsy result in the setting of a PI-RADS 4 lesion does not automatically close the case. Biopsies can miss small or awkwardly positioned tumors, and research suggests that men with a PI-RADS 4 or 5 lesion and a negative targeted biopsy should be considered for either repeat biopsy or close surveillance.¹⁶ The recommended approach can depend on where the lesion sits in the prostate. One analysis suggested that PI-RADS 4 lesions in the peripheral zone with a clearly abnormal appearance warrant targeted re-biopsy, while transition-zone lesions that overlap with benign hyperplasia features might be followed initially with a repeat MRI.¹⁷

Radiologist Disagreement on PI-RADS Scores

One uncomfortable truth worth knowing is that radiologists do not always agree on what score to assign a given lesion. Inter-observer variability is a recognized limitation, and it tends to be highest for lesions in the PI-RADS 3 to 4 range, exactly where the clinical decision to biopsy hangs in the balance. A study that had multiple radiologists score the same set of prostate MRIs found only fair to moderate agreement, with kappa coefficients ranging from about 0.31 to 0.54 for lesions scored PI-RADS 3 or above.¹⁸ Updated versions of the scoring system have improved agreement somewhat. A comparison of PI-RADS version 2 and version 2.1 found that agreement for identifying lesions as PI-RADS 4 or above improved in the peripheral zone with the newer version.¹⁹

What this means for you: if you receive a PI-RADS 4 report and have any doubt, asking for the MRI to be reviewed by a second radiologist with prostate MRI expertise is reasonable. The score you received is an informed opinion, but it is still an opinion, and a second set of eyes can shift a borderline case up or down.

The Cost and Access Question

Prostate MRI before biopsy is a relatively recent shift in the diagnostic pathway. Traditionally, an elevated PSA led directly to a transrectal ultrasound-guided biopsy, which samples tissue somewhat blindly. The MRI-first approach adds a step and a cost, but a systematic review of economic evaluations found that MRI-based pathways were actually less expensive than the traditional ultrasound-biopsy pathway in most studies analyzed, while also being more effective at identifying significant cancers across all the studies reviewed.²⁰ The savings come from avoiding unnecessary biopsies in men whose MRIs show nothing suspicious, reducing complications, and catching significant cancers earlier when treatment is less intensive.

Access remains uneven. Not every facility has a 3-Tesla MRI scanner, which provides higher-quality prostate images, and not every radiology department has staff with deep experience reading prostate MRIs. The inter-observer variability described above tends to be more pronounced at lower-volume centers.¹⁸ If you are at a center that reads relatively few prostate MRIs per year, it is worth considering whether sending your images for a second read at a higher-volume center could change your management path.

AI-Assisted Scoring on the Horizon

Artificial intelligence tools are being developed to assign PI-RADS scores from prostate MRI data. In a development study, an AI system produced scores that matched radiologists’ performance with no statistically significant difference in the rates of clinically significant cancer across PI-RADS categories 3, 4, and 5.⁶ These tools are not yet standard in clinical practice, but they hold promise for reducing the variability that comes from different radiologists interpreting the same images differently. For patients in areas with limited access to experienced prostate MRI readers, AI-assisted scoring could eventually help close the quality gap.